Journal
ALZHEIMERS & DEMENTIA
Volume 11, Issue 9, Pages 1080-1089Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2014.09.002
Keywords
Mild cognitive impairment (MCI); Alzheimer's disease; Dementia; Everyday function; Daily functioning; Instrumental activities of daily living; Informant-report; Self-report; Biomarkers; ADNI
Categories
Funding
- Alzheimer's Disease Neuroimaging Initiative (ADNI
- National Institute of Health Grant ) [U01 AG024904]
- Alzheimer's Disease Neuroimaging Initiative-2 (ADNI-2)
- Alzheimer's Disease Neuroimaging Initiative Grand Opportunity (ADNI-GO)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica, Inc.
- Biogen Idec Inc.
- Bristol-Myers Squibb Company
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
- GE Healthcare
- Innogenetics, N.V.
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Medpace, Inc.
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC.
- NeuroRx Research
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Synarc Inc.
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
- NIH grants [P30 AG010129, K01 AG030514, R01AG19771, P30AG10133, P30 AG 10129, RO1 AG031252]
Ask authors/readers for more resources
It is recognized that individuals with mild cognitive impairment (MCI) already demonstrate difficulty in aspects of daily functioning, which predicts disease progression. This study examined the relationship between self-versus informant-report of functional ability, and how those reports relate to objective disease measures across the disease spectrum (i.e. cognitively normal, MCI, Alzheimer's disease). A total of 1080 subjects with self- and/or informant-rated Everyday Cognition questionnaires were included. Objective measures included cognitive functioning, structural brain atrophy, cerebrospinal fluid abnormalities, and a marker of amyloid deposition using positron emission tomography with [F-18]AV45 (florbetapir). Overall, informant-report was consistently more associated with objective markers of disease than self-report although self-reported functional status may still have some utility in early disease. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available